abstract |
The present invention relates to serine protease mutants of the chymotrypsin superfamily, particularly +-PA mutants, that are resistant to inhibition by their cognate inhibitors, such as PAI-1 in the case of +-PA, and genes that encode the same. The present invention also relates to serine protease inhibitor mutants, particularly PAI-1 mutants, that inhibit the serine protease mutants of the present invention, particularly +-PA mutants, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents. |